Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.05 USD
Change Today -0.02 / -1.87%
Volume 92.6K
As of 5:20 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

wafergen bio-systems inc (WGBS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/15 - $5.89
52 Week Low
09/3/15 - $1.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

wafergen bio-systems inc (WGBS) Related Businessweek News

No Related Businessweek News Found

wafergen bio-systems inc (WGBS) Details

WaferGen Bio-systems, Inc. develops, manufactures, and sells systems for gene expression quantification, genotyping, and stem cell research for the life sciences and pharmaceutical drug discovery industries in the United States, Canada, Europe, and the Asia Pacific. The company offers SmartChip Real-Time PCR system, which provides a suite of gene expression and genome analysis technologies enabling biomarker discovery and validation on a single platform with the sensitivity and accuracy of real-time polymerase chain reaction (PCR). Its SmartChip Real-Time PCR system consists of two instrumentation components comprising a SmartChip MultiSample NanoDispenser for applying sample, assay, and reaction mix to the SmartChip Panels; and a SmartChip Cycler for thermal cycling and collecting data from the real-time PCR assays. The company also provides SmartChip Target Enrichment system for performing a sample preparation step prior to targeted next-generation sequencing (NGS); and Apollo 324TM library preparation System, a walk-away automation platform that offers DNA, RNA-Seq, and ChIP-Seq library preparation kits for analysis on NGS platforms. The company focuses on providing its products to researchers who perform genetic analysis and cell biology, primarily at pharmaceutical and biotech companies, academic and private research centers, and diagnostics companies involved in biomarker discovery and genetic research. WaferGen Bio-systems, Inc. was founded in 2002 and is headquartered in Fremont, California.

50 Employees
Last Reported Date: 08/7/15
Founded in 2002

wafergen bio-systems inc (WGBS) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $360.0K
Chief Financial Officer, Secretary and Treasu...
Total Annual Compensation: $77.9K
Compensation as of Fiscal Year 2014.

wafergen bio-systems inc (WGBS) Key Developments

Annoroad Selects WaferGen SmartChip (TM) Platform

Annoroad has selected the WaferGen Bio-systems, Inc. SmartChip platform for high-throughput target enrichment of BRCA1 and BRCA2 genes, SNP genotyping services and library quantification for next-generation sequencing (NGS). The system will provide the performance and flexibility to streamline key applications onto a single platform. NGS-based applications for cancer discovery in clinical research are growing, leading to a need for higher throughput, reproducibility and efficiency in an emerging market. As China's leading developer of cancer genome analysis, Annoroad will leverage the SmartChip's assay miniaturization capability, which enables the equivalent of running fifty-four 96-well plates. The system will allow Annoroad to run hundreds of human samples in only three hours on a chip 1/6th the footprint of a microtiter plate. The SmartChip platform is a flexible and high-throughput system capable of target enrichment, qPCR and SNP genotyping. The system utilizes nanoliter scale single-plex reactions for assays to provide more consistent performance and streamlined workflows, reducing the need for costly and time consuming confirmation methods that similar technologies require.

WaferGen Bio-systems, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year of 2015

WaferGen Biosystems, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $1,610,000 against $1,733,000 a year ago. Operating loss was $3,829,000 against $3,151,000 a year ago. Net loss before provision for income taxes was $3,821,000 against $2,103,000 a year ago. Net loss attributable to common stockholders was $3,821,000 or $0.67 basic and diluted per share against $2,103,000 or $2.28 basic and diluted per share a year ago. For the six months, the company reported total revenue of $2,756,000 against $3,139,000 a year ago. Operating loss was $8,403,000 against $5,804,000 a year ago. Net loss before provision for income taxes was $8,625,000 against $4,646,000 a year ago. Net loss attributable to common stockholders was $8,627,000 or $1.52 basic and diluted per share against $4,646,000 or $5.07 basic and diluted per share a year ago. For the full year of 2015, the company revised revenue guidance to $7.5 million to $7.8 million, down from $8.0 million to $8.5 million. This guidance excludes revenue from its single cell products, currently being developed.

WaferGen Bio-systems, Inc. to Report Q2, 2015 Results on Aug 05, 2015

WaferGen Bio-systems, Inc. announced that they will report Q2, 2015 results on Aug 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WGBS:US $1.05 USD -0.02

WGBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $2.94 USD +0.02
Exiqon A/S kr11.70 DKK -0.30
HTG Molecular Diagnostics Inc $5.70 USD +0.12
NanoString Technologies Inc $15.00 USD +0.14
Pacific Biosciences of California Inc $4.70 USD -0.24
View Industry Companies

Industry Analysis


Industry Average

Valuation WGBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WAFERGEN BIO-SYSTEMS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at